BROADCASTS.com

The 2024 AACR Annual Meeting heard that an \u201cefficacy signal\u201d was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma.

After reporting his group\u2019s early findings of AZD1390, an inhibitor of ataxia telangiectasia mutated (ATM) kinase studied in 115 patients with recurrent or newly diagnosed glioblastoma, first author Jonathan T. Yang MD, PhD, previously from the Memorial Sloan Kettering Cancer Center and now at UW Medicine, stepped into the Oncology Times studio at the AACR conference to tell OncTimesTalk\u2019s reporter Peter Goodwin about the safety of this new agent and the clinical value it could bring in glioblastoma.